The financing was led by Lilly Ventures with participation from other new investors, Roche Venture Fund and MP Healthcare Venture Management. Existing investors, Frazier Healthcare Ventures, Alta Partners, MediBic Alliance Technology Fund, and Novartis Venture Fund also participated in the round.
In connection with the financing, Bryan Dunnivant, principal at Lilly Ventures, will join Intradigm’s board of directors.
The company will use the series B funds to advance its RNAi therapeutics platform, which is comprised of both its siRNA intellectual property, as well as its RNAi Nanoplex delivery technology, toward the development of systemic siRNA therapeutic candidates with an initial focus on cancer targets.
Mohammad Azab, president and CEO of Intradigm, said: “The funding from our series B financing will allow us to make critical advancements in the development of our RNAi Nanoplex delivery technology, enabling the creation of a pipeline of RNAi therapeutics based on our proprietary siRNA sequences against many cancer targets.”